Contrasting GeneLink (OTCMKTS:GNLKQ) and MiMedx Group (NASDAQ:MDXG)

GeneLink (OTCMKTS:GNLKQ) and MiMedx Group (NASDAQ:MDXG) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for GeneLink and MiMedx Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneLink	0	0	0	0	0.00
MiMedx Group	1	0	6	0	2.71

MiMedx Group has a consensus price target of $8.50, suggesting a potential upside of 98.60%. Given MiMedx Group’s stronger consensus rating and higher probable upside, analysts plainly believe MiMedx Group is more favorable than GeneLink.

Earnings and Valuation

This table compares GeneLink and MiMedx Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneLink	N/A	N/A	N/A	N/A	N/A
MiMedx Group	$418.63 million	1.49	$48.58 million	$0.04	107.00

MiMedx Group has higher revenue and earnings than GeneLink.

Profitability

This table compares GeneLink and MiMedx Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneLink	N/A	N/A	N/A
MiMedx Group	1.76%	12.09%	9.22%

Institutional and Insider Ownership

79.2% of MiMedx Group shares are held by institutional investors. 14.2% of GeneLink shares are held by insiders. Comparatively, 2.5% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

MiMedx Group beats GeneLink on 8 of the 9 factors compared between the two stocks.

About GeneLink

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.

About MiMedx Group

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.